Last $4.66 USD
Change Today -0.055 / -1.17%
Volume 3.5M
CHTP On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 04/15/14 All times are local (Market data is delayed by at least 15 minutes).

chelsea therapeutics interna (CHTP) Snapshot

Open
$4.75
Previous Close
$4.72
Day High
$5.00
Day Low
$4.28
52 Week High
02/19/14 - $6.83
52 Week Low
04/24/13 - $1.68
Market Cap
365.5M
Average Volume 10 Days
2.4M
EPS TTM
$-0.24
Shares Outstanding
78.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHELSEA THERAPEUTICS INTERNA (CHTP)

chelsea therapeutics interna (CHTP) Related Businessweek News

No Related Businessweek News Found

chelsea therapeutics interna (CHTP) Details

Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of various human diseases. It is developing Northera (droxidopa), a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (Neurogenic OH) in patients with primary autonomic failure, dopamine-ß-hydroxylase, and deficiency and non-diabetic autonomic neuropathy. The company is also evaluating droxidopa in other potentially norepinephrine-related conditions and diseases, including intradialytic hypotension, fibromyalgia, freezing of gait, and adult attention deficit hyperactivity disorders. In addition, it is has a portfolio of metabolically inert antifolates for the treatment of rheumatoid arthritis, as well as for the treatment of multiple other autoimmune disorders, including psoriasis, Crohn’s diseases, uveitis, ankylosing spondylitis, inflammatory bowel diseases, cancer, and other immunological disorders. The company was founded in 2002 and is headquartered in Charlotte, North Carolina.

19 Employees
Last Reported Date: 03/11/14
Founded in 2002

chelsea therapeutics interna (CHTP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $269.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $229.0K
Chief Medical Officer and Vice President
Total Annual Compensation: $346.5K
Chief Scientific Officer and Vice President
Total Annual Compensation: $242.8K
Chief Commercial Officer and Vice President
Total Annual Compensation: $137.8K
Compensation as of Fiscal Year 2012.

chelsea therapeutics interna (CHTP) Key Developments

Chelsea Considers Strategic Alternatives

Chelsea Therapeutics International Ltd. (NasdaqCM:CHTP) is evaluating strategic alternatives.

Chelsea Therapeutics International Ltd. Announces Unaudited Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2013

Chelsea Therapeutics International Ltd. announced unaudited consolidated financial results for the fourth quarter and year ended December 31, 2013. For the quarter, the company reported operating loss $5,324,960 against $2,237,257 a year ago. Net loss was $5,320,446 or $0.07 per diluted share against $2,228,107 or $0.03 per diluted share a year ago. For the year, the company reported operating loss $16,434,356 against $31,803,503 a year ago. Net loss was $16,416,233 or $0.24 per diluted share against $231,477,643 or $0.47 per diluted share a year ago.

Chelsea Therapeutics International Ltd. Receives Accelerated FDA Approval for Orthostatic Hypotension Drug

Dainippon Sumitomo Pharma Co. Ltd. has announced that its international licensee, Chelsea Therapeutics International Ltd., has received accelerated approval from the FDA for droxidopa, or DOPS, a noradrenaline-induced adrenergic neurofunction improving agent, indicated for the treatment of neurogenic orthostatic hypotension. Chelsea plans to market the product under the brand name of "NORTHERA" in the US. In addition, it has completed Phase II studies of the agent for fibromyalgia and for intradialytic hypotension. DOPS, a precursor of noradrenaline (NA), is converted to NA thereby improving symptoms related to NA deficiency.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CHTP:US $4.66 USD -0.055

CHTP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CHTP.
View Industry Companies
 

Industry Analysis

CHTP

Industry Average

Valuation CHTP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 8.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHELSEA THERAPEUTICS INTERNA, please visit www.chelseatherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.